247 related articles for article (PubMed ID: 35058688)
1. Current Perspectives in the Treatment of Locally Advanced Basal Cell Carcinoma.
Gupta N; Ruiz ES
Drug Des Devel Ther; 2022; 16():183-190. PubMed ID: 35058688
[TBL] [Abstract][Full Text] [Related]
2. The current clinical approach to difficult-to-treat basal cell carcinomas.
Di Brizzi EV; Argenziano G; Brancaccio G; Scharf C; Ronchi A; Moscarella E
Expert Rev Anticancer Ther; 2023 Jan; 23(1):43-56. PubMed ID: 36579630
[TBL] [Abstract][Full Text] [Related]
3. Advanced basal cell carcinoma.
Wollina U; Tchernev G
Wien Med Wochenschr; 2013 Aug; 163(15-16):347-53. PubMed ID: 23589318
[TBL] [Abstract][Full Text] [Related]
4. Current landscape for treatment of advanced basal cell carcinoma.
Foley P
Australas J Dermatol; 2015 Mar; 56 Suppl 1():1-7. PubMed ID: 25715811
[TBL] [Abstract][Full Text] [Related]
5. Hedgehog Inhibitor Induction with Addition of Concurrent Superficial Radiotherapy in Patients with Locally Advanced Basal Cell Carcinoma: A Case Series.
Weissman JP; Samlowski W; Meoz R
Oncologist; 2021 Dec; 26(12):e2247-e2253. PubMed ID: 34472658
[TBL] [Abstract][Full Text] [Related]
6. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus.
Peris K; Licitra L; Ascierto PA; Corvò R; Simonacci M; Picciotto F; Gualdi G; Pellacani G; Santoro A
Future Oncol; 2015; 11(4):703-12. PubMed ID: 25686123
[TBL] [Abstract][Full Text] [Related]
7. Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib.
Hehlgans S; Booms P; Güllülü Ö; Sader R; Rödel C; Balermpas P; Rödel F; Ghanaati S
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142876
[TBL] [Abstract][Full Text] [Related]
8. [Therapy of basal cell carcinoma].
Schmitz L; Dirschka T
Hautarzt; 2016 Jun; 67(6):483-99. PubMed ID: 27206448
[TBL] [Abstract][Full Text] [Related]
9. Identifying patients at risk for recurrent or advanced BCC.
Hamid O; Goldenberg G
J Drugs Dermatol; 2013 Nov; 12(11):1246-52; quiz 1253-4. PubMed ID: 24196332
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and outcomes for patients with locally advanced basal cell carcinoma before availability of Hedgehog pathway inhibitors: a retrospective chart review.
Lear JT; Basset-Seguin N; Kaatz M; Jouary T; Mortier L; Fabrizio T; Herd R; Leverkus M; Revil C; Page DR; Grob JJ
Eur J Dermatol; 2017 Aug; 27(4):386-392. PubMed ID: 28862133
[TBL] [Abstract][Full Text] [Related]
11. Induction Hedgehog pathway inhibition followed by combined-modality radiotherapy for basal cell carcinoma.
Raleigh DR; Algazi A; Arron ST; Neuhaus IM; Yom SS
Br J Dermatol; 2015 Aug; 173(2):544-6. PubMed ID: 25702621
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
13. High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature.
Campione E; Di Prete M; Lozzi F; Lanna C; Spallone G; Mazzeo M; Cosio T; Rapanotti C; Dika E; Gaziano R; Orlandi A; Bianchi L
Chemotherapy; 2020; 65(1-2):2-10. PubMed ID: 32777789
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial.
Véron M; Chevret S; Grob JJ; Beylot-Barry M; Saiag P; Fléchon A; You B; Maubec E; Jouary T; Toulemonde E; Jamme P; Gambotti L; Lamrani-Ghaouti A; Dupuy A; Lebbe C; Seguin NB; Houede N; Leccia MT; Le Du F; de Pontville M; Gaudy-Marquestre C; Guillot B; Simon C; Marabelle A; Mortier L
Eur J Cancer; 2022 Dec; 177():103-111. PubMed ID: 36335780
[TBL] [Abstract][Full Text] [Related]
15. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
Leavitt E; Lask G; Martin S
Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379
[TBL] [Abstract][Full Text] [Related]
16. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023.
Peris K; Fargnoli MC; Kaufmann R; Arenberger P; Bastholt L; Seguin NB; Bataille V; Brochez L; Del Marmol V; Dummer R; Forsea AM; Gaudy-Marqueste C; Harwood CA; Hauschild A; Höller C; Kandolf L; Kellerners-Smeets NWJ; Lallas A; Leiter U; Malvehy J; Marinović B; Mijuskovic Z; Moreno-Ramirez D; Nagore E; Nathan P; Stratigos AJ; Stockfleth E; Tagliaferri L; Trakatelli M; Vieira R; Zalaudek I; Garbe C;
Eur J Cancer; 2023 Oct; 192():113254. PubMed ID: 37604067
[TBL] [Abstract][Full Text] [Related]
17. Emerging trends in the treatment of advanced basal cell carcinoma.
Migden MR; Chang ALS; Dirix L; Stratigos AJ; Lear JT
Cancer Treat Rev; 2018 Mar; 64():1-10. PubMed ID: 29407368
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Hedgehog pathway inhibitors in Basal cell carcinoma.
Basset-Seguin N; Sharpe HJ; de Sauvage FJ
Mol Cancer Ther; 2015 Mar; 14(3):633-41. PubMed ID: 25585509
[TBL] [Abstract][Full Text] [Related]
19. Vismodegib: the first drug approved for advanced and metastatic basal cell carcinoma.
Dubey AK; Dubey S; Handu SS; Qazi MA
J Postgrad Med; 2013; 59(1):48-50. PubMed ID: 23525058
[TBL] [Abstract][Full Text] [Related]
20. Treatment of locally advanced and metastatic basosquamous carcinoma, navigating among sonic hedgehog pathway inhibitors, immune checkpoint inhibitors, chemotherapy, and radiotherapy: A case series and literature review.
Zelin E; Mazzoletti V; Cavallo F; Nardello C; Corio A; Toffoli L; Tagliaferri L; Conforti C; Di Meo N; Zalaudek I
Australas J Dermatol; 2024 Mar; 65(2):103-113. PubMed ID: 37927116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]